Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00136539
Recruitment Status : Completed
First Posted : August 29, 2005
Last Update Posted : February 18, 2013
Dana-Farber Cancer Institute
Genentech, Inc.
Bristol-Myers Squibb
Massachusetts General Hospital
Beth Israel Deaconess Medical Center
Harvard Vanguard Medical Associates
Brigham and Women's Hospital
Information provided by (Responsible Party):
Harold J. Burstein, MD, PhD, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : November 2006
  Actual Study Completion Date : March 2012